Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beximco PharmaceuticalsBXMPY 94 Cash Ratio is 0.76 as of Mar. 2026, which is 744% above its 10-year median of 0.09. GuruFocus rates BXMPY with a GF Score™ of 94/100. The stock has 5 warning signs investors should review. Among 971 Drug Manufacturers companies, Beximco Pharmaceuticals ranks better than 56.13% on this metric.
Beximco Pharmaceuticals has a Cash Ratio of 0.76. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Beximco Pharmaceuticals's Cash Ratio or its related term are showing as below:
BXMPY'
s Cash Ratio Range Over the Past 10 Years
Min: 0.04 Med: 0.09 Max: 0.76
Current: 0.76
During the past 13 years, Beximco Pharmaceuticals's highest Cash Ratio was 0.76. The lowest was 0.04. And the median was 0.09.
BXMPY's Cash Ratio is ranked better than 56.13% of 971
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs BXMPY: 0.76
Beximco Pharmaceuticals (OTCPK:BXMPY) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Beximco Pharmaceuticals Cash Ratio Related Terms
Beximco Pharmaceuticals Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals (BXMPY) has a Cash Ratio of 0.76 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Beximco Pharmaceuticals and its competitors. This is 744% above median its historical median of 0.09. Over the past decade, Beximco Pharmaceuticals' Cash Ratio has ranged from 0.04 to 0.76. According to the industry distribution chart, Beximco Pharmaceuticals ranks #426 out of 971 companies in the Drug Manufacturers industry, placing it in the top 43.9%.
Is Beximco Pharmaceuticals' Cash Ratio too high?
Beximco Pharmaceuticals' current Cash Ratio of 0.76 is 744% above median its 10-year median of 0.09. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.76. The Drug Manufacturers industry median Cash Ratio is 0.60. Beximco Pharmaceuticals' value of 0.76 is 26.7% above this industry median. Based on the distribution chart, Beximco Pharmaceuticals ranks #426 out of 971 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beximco Pharmaceuticals has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Cash Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #426 out of 971 companies for Cash Ratio. This puts Beximco Pharmaceuticals in the upper half of its industry. The industry median Cash Ratio is 0.60. Beximco Pharmaceuticals' value of 0.76 is 26.7% above this benchmark. Historically, Beximco Pharmaceuticals' own Cash Ratio has ranged from 0.04 to 0.76 over the past decade. While the company's 10-year median is 0.09 vs. the industry median of 0.60, Beximco Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.60, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current Cash Ratio of 0.76 is 26.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current Cash Ratio is 0.76, which is 744% above median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current Cash Ratio of 0.76. The current Cash Ratio is 0.76, which is 744% above median its 10-year median of 0.09 and 26.7% above the Drug Manufacturers industry median of 0.60. Beximco Pharmaceuticals' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current Cash Ratio is 0.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 
